Contrast-enhanced Ultrasound for Complex Kidney Lesion Diagnosis in Patients With CKD Extension

PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

August 28, 2017

Primary Completion Date

March 19, 2021

Study Completion Date

March 19, 2021

Conditions
Chronic Kidney DiseasesCystic Kidney Disease
Interventions
DRUG

Perflutren Lipid microsphere

Perflutren will be administered in a bolus or continuous infusion using the dosing range and administration type within the perflutren prescribing information.Once perflutren lipid has been administered, the transducer is maintained in a constant position over the area of interest to show the target lesion in order to assess the enhancement pattern during the early, mid and late vascular phases. Images will also be taken of kidney parenchyma in a suitable longitudinal plane.If there are multiple lesions in one subject requiring a second dose, the subject will have the option to undergo a 2nd contrast-enhanced study 30-minutes after the initial contrast dose, per dosing instructions in the package insert.

Trial Locations (1)

27599-7510

University of North Carolina of Chapel hill, Chapel Hill

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Lantheus Medical Imaging

INDUSTRY

lead

University of North Carolina, Chapel Hill

OTHER

NCT03196076 - Contrast-enhanced Ultrasound for Complex Kidney Lesion Diagnosis in Patients With CKD Extension | Biotech Hunter | Biotech Hunter